Sildenafil reduces signs of oxidative stress in pulmonary arterial hypertension: Evaluation by fatty acid composition, level of hydroxynonenal and heart rate variability

Redox Biology

Volumn 7, Issue , 2016, Pages 48-57

  Semen, Khrystyna ^a   Yelisyeyeva, Olha ^a   Jarocka Karpowicz, Iwona ^b   Kaminskyy, Danylo ^a   Solovey, Lyubomyr ^c   Skrzydlewska, Elzbieta ^b   Yavorskyi, Ostap ^a  

^a DANYLO HALYTSKY LVIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c Lviv Regional Clinical Hospital   (Ukraine)

Author keywords

Fatty acid composition; Heart rate variability; Hydroxynonenal; Oxidative stress; Pulmonary arterial hypertension; Sildenafil

Indexed keywords

4 HYDROXYNONENAL; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ARACHIDIC ACID; ARACHIDONIC ACID; BEHENIC ACID; DOCOSAHEXAENOIC ACID; DOCOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; NERVONIC ACID; NITRIC OXIDE SYNTHASE; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; PHOSPHOLIPID; SILDENAFIL; STEARIC ACID; UNCLASSIFIED DRUG; ALDEHYDE; FATTY ACID; NITRIC OXIDE; TERT-4-HYDROXY-2-NONENAL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BIOAVAILABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EXERCISE; FATTY ACID ANALYSIS; FEMALE; HEADACHE; HEART RATE VARIABILITY; HEART RHYTHM; HUMAN; LIPID COMPOSITION; LIPID PEROXIDATION; LUNG HEMODYNAMICS; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; DRUG EFFECTS; HEART RATE; HYPERTENSION, PULMONARY; METABOLISM; PATHOPHYSIOLOGY; YOUNG ADULT;

ADULT; ALDEHYDES; FATTY ACIDS; FEMALE; HEART RATE; HUMANS; HYPERTENSION, PULMONARY; LIPID PEROXIDATION; MALE; NITRIC OXIDE; OXIDATIVE STRESS; SILDENAFIL CITRATE; YOUNG ADULT;

EID: 84948807412     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2015.11.009     Document Type: Article

References (82)

1. Aggarwal S., Gross C.M., Sharma S., Fineman J.R., Black S.M. Reactive oxygen species in pulmonary vascular remodeling. Compr. Physiol. 2013, 3:1011-1034.
2. Al-Husseini A., Wijesinghe D.S., Farkas L., Kraskauskas D., Drake J.I., Van Tassel B., Abbate A., Chalfant C.E., Voelkel N.F. Increased eicosanoid levels in the sugen/chronic hypoxia model of severe pulmonary hypertension. Plos One 2015, 10:e0120157.
3. Balakumar P., Taneja G. Fish oil and vascular endothelial protection: bench to bedside. Free Radic. Biol. Med. 2012, 53:271-279.
4. Barnes J., Dweik R.A. Is pulmonary hypertension a metabolic disease?. Am. J. Respir. Crit. Care Med. 2014, 190:973-975.
5. Benza R.L., Miller Dave P., Barst Robyn J., Badesch David B., Frost Adaani E., McGoon Michael D. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. CHEST J. 2012, 142:448-456.
6. Can M.M., Kaymaz C., Pochi N., Aktimur T. Impact of pulmonary arterial hypertension and its therapy on indices of heart rate variability. Off. Publ. Med. Assoc. Zenica -Doboj. Cant. Bosnia Herzeg. 2013, 10:249-253.
7. Chapple S.J., Cheng X., Mann G.E. Effects of 4-hydroxynonenal on vascular endothelial and smooth muscle cell redox signaling and function in health and disease. Redox Biol. 2013, 1:319-331.
8. Chen C.-H., Lihan Sun, Mochly-Rosen Daria Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc. Res. 2010, 88:51-57.
9. Chen J., Shearer G.C., Chen Q., Healy C.L., Beyer A.J., Nareddy V.B., Gerdes A.M., Harris W.S., O'Connell T.D., Wang D. Omega-3 fatty acids prevent pressure overload-induced cardiac fibrosis through activation of cyclic GMP/protein kinase G signaling in cardiac fibroblasts. Circulation 2011, 123:584-593.
10. L. Chen, J.-P. Zhou, D.-B. Kuang, J. Tang, Y.-J. Li, X.-P Chen, 4-HNE increases intracellular ADMA levels in cultured HUVECs: evidence for miR-21-dependent mechanisms, 2013.
11. Christie W.W. Preparation of ester derivatives of fatty acids for chromatographic analysis. Adv. Lipid Methodol. 1993, 2:e111.
12. Christman B.W. Lipid mediator dysregulation in primary pulmonary hypertension. CHEST J. 1998, 114:205S-207S.
13. Cracowski J.-L., Degano B., Chabot F., Labarère J., Schwedhelm E., Monneret D., Iuliano L., Schwebel C., Chaouat A., Reynaud-Gaubert M. Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension. CHEST J. 2012, 142:869-876.
14. Daiber A., Steffen Daub, Markus Bachschmid, Stefan Schildknecht, Matthias Oelze, Sebastian Steven, Patrick Schmidt, Alexandra Megner, Masayuki Wada, Tadashi Tanabe Protein tyrosine nitration and thiol oxidation by peroxynitrite-Strategies to prevent these oxidative modifications. Int. J. Mol. Sci. 2013, 14:7542-7570.
15. Dobrzyńska I., Szachowicz-Petelska B., Skrzydlewska E., Figaszewski Z. Effect of sweet grass (Hierochloe odorata) on the physico-chemical properties of liver cell membranes from rats intoxicated with ethanol. Environ. Toxicol. Pharmacol. 2013, 35:247-253.
16. Dorrance A.M., Graham D., Dominiczak A., Fraser R. Inhibition of nitric oxide synthesis increases erythrocyte membrane fluidity and unsaturated fatty acid content. Am. J. Hypertens. 2000, 13:1194-1202.
17. 2+ signaling and NO production in endothelial cells. Antioxid. Redox Signal 2003, 5:147-153.
18. Ferreri C., Chatgilialoglu C. Role of fatty acid-based functional lipidomics in the development of molecular diagnostic tools. Expert. Rev. Mol. Diagn. 2012, 12:767-780.
19. Galiè N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 2005, 353:2148-2157.
20. Galiè N., Hoeper M.M., Humbert M., Torbicki A., Vachiery J.-L., Barbera J.A., Beghetti M., Corris P., Gaine S., Gibbs J.S. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2009, 30:2493-2537.
21. Galiè N., Humbert Marc, Vachiery, Jean-Luc Gibbs, Simon, Lang Irene, Torbicki, Adam Simonneau, Gérald, Peacock Andrew, Noordegraaf Anton Vonk, Beghetti Maurice ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Respir. J. 2015, 46:903-975.
22. Gatbonton-Schwager T.N., Sadhukhan Sushabhan, Zhang Guo-Fang, Letterio John J., Tochtrop Gregory P. Identification of a negative feedback loop in biological oxidant formation fegulated by 4-hydroxy-2-(E)-nonenal. Redox Biol. 2014, 2:755-763.
23. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., Channick R., Keogh A.M., Gomez-Sanchez M.A., Kneussl M., Grimminger F. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 2004, 43:S68-S72.
24. Gong D., Zhang Hao, Hu Shengshou Mitochondrial aldehyde dehydrogenase 2 activation and cardioprotection. J. Mol. Cell. Cardiol. 2013, 55:58-63.
25. Graham B.B., Kumar R., Mickael C., Sanders L., Gebreab L., Huber K.M., Perez M., Smith-Jones P., Serkova N.J., Tuder R.M. Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2015, 309:L435-L440.
26. Gremmels H., Bevers L.M., Fledderus J.O., Braam B., van Zonneveld A.J., Verhaar M.C., Joles J.A. Oleic acid increases mitochondrial reactive oxygen species production and decreases endothelial nitric oxide synthase activity in cultured endothelial cells. Eur. J. Pharmacol. 2015, 751:67-72.
27. Hattori Y., Hattori S., Kasai K. 4-Hydroxynonenal prevents no production in vascular smooth muscle cells by inhibiting nuclear factor-κB-dependent transcriptional activation of inducible NO synthase. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1179-1183.
28. Heart R. Heart rate variability standards of measurement, physiological interpretation, and clinical use. Circulation 1996, 93:1043-1065.
29. Hemnes A.R., Zaiman A., Champion H.C. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am. J. Physiol.-Lung Cell. Mol. Physiol. 2008, 294:L24-L33.
30. Hiram R., Rizcallah E., Sirois C., Sirois M., Morin C., Fortin S., Rousseau E. Resolvin D1 reverses reactivity and Ca2+ sensitivity induced by ET-1, TNF-α, and IL-6 in the human pulmonary artery. Am. J. Physiol.-Heart Circ. Physiol. 2014, 307:H1547-H1558.
31. M. Humbert, H.-A. Ghofrani, The molecular targets of approved treatments for pulmonary arterial hypertension. Thorax, 2015, thoraxjnl-2015-207170.
32. Irodova N., Lankin V.Z., Konovalova G.K., Kochetov A.G., Chazova I.E. Oxidative stress in patients with primary pulmonary hypertension. Bull. Exp. Biol. Med. 2002, 133:580-582.
33. Jung U.J., Torrejon C., Tighe A.P., Deckelbaum R.J. n-3 Fatty acids and cardiovascular disease: mechanisms underlying beneficial effects. Am. J. Clin. Nutr. 2008, 87(Suppl.):2003S-2009S.
34. Kafi S.A., Scillia P., Mélot C., Gevenois P.A., Pagnamenta A., Naeije R. Abnormal pulmonary vascular tone in canine oleic acid lung injury. Crit. Care Med. 2002, 30:1565-1569.
35. S. Khambata Rayomand, M., Ahluwalia Amrita, "Repurposing" of xanthine oxidoreductase as a nitrite reductase: a new paradigm for therapeutic targeting in hypertension. ANTIOXIDANTS & REDOX SIGNALING, 2015.
36. Kiss T., Kovacs K., Komocsi A., Tornyos A., Zalan P., Sumegi B., Gallyas F. Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt. Plos One 2014, 9:e104890.
37. La Rovere M.T., Christensen J.H. The autonomic nervous system and cardiovascular disease: role of n-3 PUFAs. Vasc. Pharmacol. 2015, 71:1-10.
38. La Rovere M.T., Pinna G.D., Maestri R., Barlera S., Bernardinangeli M., Veniani M., Nicolosi G.L., Marchioli R., Tavazzi L. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial. Eur. J. Heart Fail. 2012, 14:1410-1419.
39. Lee C.-H., Lee S.-D., Ou H.-C., Lai S.-C., Cheng Y.-J. Eicosapentaenoic acid protects against palmitic acid-induced endothelial dysfunction via activation of the AMPK/eNOS pathway. Int. J. Mol. Sci. 2014, 15:10334-10349.
40. Lemmens K.J., Sthijns M.M., van der Vijgh W.J., Bast A., Haenen G.R. The antioxidant flavonoid monoHER provides efficient protection and induces the innate Nrf2 mediated adaptation in endothelial cells subjected to oxidative stress. PharmaNutrition 2014, 2:69-74.
41. Liu X-m Peyton K.J., Wang X., Durante W. Sildenafil stimulates the expression of gaseous monoxide-generating enzymes in vascular smooth muscle cells via distinct signaling pathways. Biochem. Pharmacol. 2012, 84:1045-1054.
42. Maggiorini M. Prevention and treatment of high-altitude pulmonary edema. Prog. Cardiovasc. Dis. 2010, 52:500-506.
43. Matesanz N., Park G., McAllister H., Leahey W., Devine A., McVeigh G.E., Gardiner T.A., McDonald D.M. Docosahexaenoic acid improves the nitroso-redox balance and reduces VEGF-mediated angiogenic signaling in microvascular endothelial cells. Investig. Ophthalmol. Vis. Sci. 2010, 51:6815.
44. McMahon M., Lamont D.J., Beattie K.A., Hayes J.D. Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals. Proc. Natl. Acad. Sci. 2010, 107:18838-18843.
45. Mohan I.K., Das U. Effect of l-arginine-nitric oxide system on the metabolism of essential fatty acids in chemical-induced diabetes mellitus. Prostaglandins Leukot. Essent. Fat. Acids 2000, 62:35-46.
46. Morin C., Hiram R., Rousseau E., Blier P.U., Fortin S. Docosapentaenoic acid monoacylglyceride reduces inflammation and vascular remodeling in experimental pulmonary hypertension. Am. J. Physiol.-Heart Circ. Physiol. 2014, 307:H574-H586.
47. Musicki B., Bivalacqua T.J., Champion H.C., Burnett A.L. Sildenafil promotes eNOS activation and inhibits NADPH oxidase in the transgenic sickle cell mouse penis. J. Sex. Med. 2014, 11:424-430.
48. Nagendran J., Archer Stephen L., Soliman Daniel, Gurtu Vikram, Moudgil Rohit, Haromy Alois, Aubin Chantal St, Webster Linda, Rebeyka Ivan M., Ross David B. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007, 116:238-248.
49. Park H.-S., Park J.-W., Kim H.-J., Choi C.W., Lee H.-J., Kim B.I., Chun Y.-S. Sildenafil alleviates bronchopulmonary dysplasia in neonatal rats by activating the hypoxia-inducible factor signaling pathway. Am. J. Respir. Cell. Mol. Biol. 2013, 48:105-113.
50. Pulmonary Circulation: Diseases and Their Treatment 2011, CRC Press, Taylor & Francis, Boca Raton, FL, USA. A.J. Peacock, R. Naeije, L.J. Rubin (Eds.).
51. Peers C., Bauer C.C., Boyle J.P., Scragg J.L., Dallas M.L. Modulation of ion channels by hydrogen sulfide. Antioxid. Redox Signal. 2012, 17:95-105.
52. Prabhakar N.R., Semenza G.L. Gaseous messengers in oxygen sensing. J. Mol. Med. 2012, 90:265-272.
53. Pryor W.A., Houk K.N., Foote C.S., Fukuto J.M., Ignarro L.J., Squadrito G.L., Davies K.J.A. Free radical biology and medicine: it's a gas, man!. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2006, 291:R491-R511.
54. Rabinovitch M., Guignabert C., Humbert M., Nicolls M.R. Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 2014, 115:165-175.
55. Rubin L.J., Badesch D.B., Fleming T.R., Galiè N., Simonneau G., Ghofrani H.A., Oakes M., Layton G., Serdarevic-Pehar M., McLaughlin V.V. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. CHEST J. 2011, 140:1274-1283.
56. Rudolph V., Freeman B.A. Cardiovascular consequences when nitric oxide and lipid signaling converge. Circ. Res. 2009, 105:511-522.
57. Saraswathi V., Wu G., Toborek M., Hennig B. Linoleic acid-induced endothelial activation role of calcium and peroxynitrite signaling. J. Lipid Res. 2004, 45:794-804.
58. Semen K., den Hartog G., Kaminskyy D., Sirota T., Maij N. Redox modulation by Amaranth oil in human lung fibroblasts. Nat. Prod. Chem. Res. 2013, 2:2.
59. Skrzydlewska E., Sulkowski S., Koda M., Zalewski B., Kanczuga-Koda L., Sulkowska M. Lipid peroxidation and antioxidant status in colorectal cancer. World J. Gastroenterol.: WJG 2005, 11:403-406.
60. Starkov A.A. An update on the role of mitochondrial α-ketoglutarate dehydrogenase in oxidative stress. Mol. Cell. Neurosci. 2013, 55:13-16.
61. Stenmark K.R., Morganroth M.L., Remigio L.K., Voelkel N.F., Murphy R.C., Henson P.M., Mathias M.M., Reeves J.T. Alveolar inflammation and arachidonate metabolism in monocrotaline-induced pulmonary hypertension. Am. J. Physiol.-Heart Circ. Physiol. 1985, 248:H859-H866.
62. Tabima D.M., Frizzell Sheila, Gladwin Mark T. Reactive oxygen and nitrogen species in pulmonary hypertension. Free Radic. Biol. Med. 2012, 52:1970-1986.
63. Taibi G., Carruba Giuseppe, Miceli Vitale, Cocciadiferro Letizia, Cucchiara Angela, Nicotra Concetta M.A. Sildenafil protects epithelial cell through the inhibition of xanthine oxidase and the impairment of ROS production. Free. Radic. Res. 2010, 44:232-239.
64. 2+ levels in endothelial cells. J. Mol. Endocrinol. 2011, 47:315-326.
65. Thomas S.R., Witting P.K., Drummond G.R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid. Redox Signal. 2008, 10:1713-1765.
66. R.M. Tuder, S.L. Archer, P. Dorfmüller, S.C.Erzurum, C. Guignabert, E. Michelakis, M. Rabinovitch, R. Schermuly, K.R.Stenmark and N.W. Morrell, Relevant issues in the pathology andpathobiology of pulmonary hypertension, J. Am. Coll. Cardiol. 62 (25), Suppl. D, D4-D12.
67. Tuder R.M., Cool Carlyne D., Geraci Mark W., Wang Jun, Abman Steven H., Wright Laurel, Badesch David, Voelkel Norbert F. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 1999, 159:1925-1932.
68. Usatyuk P.V., Natarajan V. Hydroxyalkenals and oxidized phospholipids modulation of endothelial cytoskeleton, focal adhesion and adherens junction proteins in regulating endothelial barrier function. Microvasc. Res. 2012, 83:45-55.
69. Voelkel N.F., Chang S.W., McDonnell T.J., Westcott J.Y., Haynes J. Role of membrane lipids in the control of normal vascular tone. Am. Rev. Respir. Dis. 1987, 136:214-217.
70. Walker B.R., Voelkel N.F., Reeves J.T. Pulmonary pressor response after prostaglandin synthesis inhibition in conscious dogs. J. Appl. Physiol. 1982, 52:705-709.
71. Wensel R., Jilek C., Dörr M., Francis D., Stadler H., Lange T., Blumberg F., Opitz C., Pfeifer M., Ewert R. Impaired cardiac autonomic control relates to disease severity in pulmonary hypertension. Eur. Respir. J. 2009, 34:895-901.
72. Whitsett J., Picklo M.J., Vasquez-Vivar J. 4-Hydroxy-2-nonenal increases superoxide anion radical in endothelial cells via stimulated GTP cyclohydrolase proteasomal degradation. Arterioscler. Thromb., Vasc. Biol. 2007, 27:2340-2347.
73. Yelisyeyeva O., Semen K., Ostrovska G., Kaminskyy D., Sirota T., Zarkovic N., Mazur D., Lutsyk O., Rybalchenko K., Bast A. The effect of Amaranth oil on monolayers of artificial lipids and hepatocyte plasma membranes with adrenalin-induced stress. Food Chem. 2014, 147:152-159.
74. Yelisyeyeva O., Semen K., Zarkovic N., Kaminskyy D., Lutsyk O., Rybalchenko V. Activation of aerobic metabolism by Amaranth oil improves heart rate variability both in athletes and patients with type 2 diabetes mellitus. Arch. Physiol. Biochem. 2012, 118:47-57.
75. Yoshino K., Sano M., Fujita M., Tomita I. Formation of aliphatic aldehydes in rat plasma and liver due to vitamin E deficiency. Chem. Pharm. Bull. 1986, 34:5184-5187.
76. Young C.N., Fisher J.P., Gallagher K.M., Whaley-Connell A., Chaudhary K., Victor R.G., Thomas G.D., Fadel P.J. Inhibition of nitric oxide synthase evokes central sympatho-excitation in healthy humans. J. Physiol. 2009, 587:4977-4986.
77. Zakharchenko M.V., Zakharchenko A., Khunderyakova N., Tutukina M., Simonova M., Vasilieva A., Romanova O., Fedotcheva N., Litvinova E., Maevsky E. Burst of succinate dehydrogenase and α-ketoglutarate dehydrogenase activity in concert with the expression of genes coding for respiratory chain proteins underlies short-term beneficial physiological stress in mitochondria. Int. J. Biochem. Cell. Biol. 2013, 45:190-200.
78. Zarkovic N. 4-Hydroxynonenal as a bioactive marker of pathophysiological processes. Mol. Asp. Med. 2003, 24:281-291.
79. Zhang S., Yang T., Xu X., Wang M., Zhong L., Yang Y., Zhai Z., Xiao F., Wang C. Oxidative stress and nitric oxide signaling related biomarkers in patients with pulmonary hypertension: a case control study. BMC Pulm. Med. 2015, 15:50.
80. Zheng J., Huang T., Yu Y., Hu X., Yang B., Li D. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr. 2012, 15:725-737.
81. Zou M., Martin Christian, Ullrich Volker Tyrosine nitration as a mechanism of selective inactivation of prostacyclin synthase by peroxynitrite. Biol. Chem. 1997, 378:707-714.
82. Zuckerbraun B.S., George P., Gladwin M.T. Nitrite in pulmonary arterial hypertension: therapeutic avenues in the setting of dysregulated arginine/nitric oxide synthase signalling. Cardiovasc. Res. 2011, 89:542-552.